Balaxi Pharma

{
  "main_header": {
    "sid": 999933,
    "name": "Balaxi Pharma",
    "stock_name": "Balaxi Pharma",
    "full_name": "Balaxi Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/balaxi-pharma",
    "exchange": 1,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "24.20",
    "chg": -0.12,
    "chgp": "-0.49%",
    "dir": -1,
    "prev_price": "24.32",
    "mcapval": "136.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "BALAXI",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 5,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE618N01022",
    "curr_date": "Aug 10, 03:31 PM",
    "curr_time": "16:01 PM",
    "last_traded_at": "Aug 10, 03:31 PM IST",
    "bse_nse_vol": 23098,
    "exc_status": "Active",
    "traded_date": "Aug 10, 2026",
    "traded_date_str": "2026 08 10",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/balaxi-pharma-999933-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Balaxi Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/balaxi-pharmaceuticals-ltd-is-rated-strong-sell-4145067",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/BalaxiPharmaceu_mojoScore_4145067.png",
        "date": "2026-08-10 10:10:47",
        "description": "Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 10 August 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Balaxi Pharmaceuticals Gains 1.76%: Quarterly Recovery Amid Lingering Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/balaxi-pharmaceuticals-gains-176-quarterly-recovery-amid-lingering-challenges-4143221",
        "imagepath": "",
        "date": "2026-08-08 14:00:08",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>3 Aug:</strong> Stock opens at Rs.24.00, Sensex gains 0.82%</p>\n                    <p><strong>5 Aug:</strong> Q1 FY27 results reveal strong revenue recovery</p>\n                    <p><strong>6 Aug:</strong> Flat quarterly performance amid long-term challenges reported</p>\n                    <p><strong>7 Aug:</strong> Week closes at Rs.24.32, up 1.76% for the week</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.24.00</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.24.32</div><div..."
      },
      {
        "title": "Are Balaxi Pharmaceuticals Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-balaxi-pharmaceuticals-ltd-latest-results-good-or-bad-4140375",
        "imagepath": "",
        "date": "2026-08-06 19:22:18",
        "description": "Balaxi Pharmaceuticals Ltd's latest financial results for the quarter ending June 2026 reveal a complex operational landscape. The company reported a net sales figure of ₹80.68 crores, reflecting a year-on-year growth of 14.05%, which is an improvement compared to the previous year's growth of 7.80%. Additionally, the consolidated net profit surged to ₹1.30 crores, marking a significant year-on-year increase of 348.28%, a stark contrast to the negative performance recorded in the same quarter last year.\n\nDespite these positive indicators, the operating profit margin, excluding other income, stood at 5.78%, which represents a slight decline from 5.85% in the previous year. This suggests that while revenue growth is being achieved, the company is facing challenges in maintaining profitability levels, indicating potential operational instability.\n\nThe company's recent performance has led to an adjustment in it..."
      },
      {
        "title": "Balaxi Pharmaceuticals Reports Flat Quarterly Performance Amid Long-Term Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/balaxi-pharmaceuticals-reports-flat-quarterly-performance-amid-long-term-challenges-4138990",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/BalaxiPharmaceu_fintrenddot_4138990.png",
        "date": "2026-08-06 08:00:25",
        "description": "Balaxi Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended June 2026, signalling a pause in its recent negative trend. Despite achieving record quarterly sales and profitability metrics, the company continues to face challenges in profitability growth and cash reserves, reflecting a complex financial landscape for investors to navigate."
      },
      {
        "title": "Balaxi Pharmaceuticals Q1 FY27: Strong Revenue Recovery Masks Deep Structural Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/balaxi-pharmaceuticals-q1-fy27-strong-revenue-recovery-masks-deep-structural-concerns-4138584",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/BalaxiPharmaceu_quaterlyResult_4138584.png",
        "date": "2026-08-05 21:18:40",
        "description": "Balaxi Pharmaceuticals Ltd. reported a net profit of ₹1.30 crores for Q1 FY27, representing a substantial sequential improvement of 113.11% from ₹0.61 crores in Q4 FY26 and a dramatic year-on-year surge of 348.28% from ₹0.29 crores in Q1 FY26. The micro-cap pharmaceutical company, with a market capitalisation of ₹136.00 crores, delivered revenue of ₹80.68 crores for the quarter, marking a 14.10% sequential growth and 14.05% year-on-year expansion."
      },
      {
        "title": "Balaxi Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/balaxi-pharmaceuticals-ltd-is-rated-strong-sell-4128537",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/BalaxiPharmaceu_mojoScore_4128537.png",
        "date": "2026-07-30 10:10:29",
        "description": "Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 29 May 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 30 July 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Balaxi Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/balaxi-pharmaceuticals-ltd-is-rated-strong-sell-4107996",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/BalaxiPharmaceu_mojoScore_4107996.png",
        "date": "2026-07-19 10:10:15",
        "description": "Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 29 May 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 19 July 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Balaxi Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/balaxi-pharmaceuticals-ltd-is-rated-strong-sell-4093502",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/BalaxiPharmaceu_mojoScore_4093502.png",
        "date": "2026-07-08 10:10:27",
        "description": "Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 29 May 2026, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 08 July 2026, providing investors with the latest perspective on the company’s position."
      },
      {
        "title": "Balaxi Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/balaxi-pharmaceuticals-ltd-is-rated-strong-sell-4075009",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/BalaxiPharmaceu_mojoScore_4075009.png",
        "date": "2026-06-27 10:10:21",
        "description": "Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 29 May 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 27 June 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market standing."
      }
    ],
    "total": 126,
    "sid": "999933",
    "stock_news_url": "https://www.marketsmojo.com/news/balaxi-pharmaceuticals-999933"
  },
  "announcements": [
    {
      "details": "Balaxi Ventures Limited has informed the Exchange regarding Resignation of Mr Nidhin Jose as Chief Financial Officer of the company w.e.f. November 30, 2019.",
      "source": "NSE",
      "caption": "Balaxi Ventures Limited - Resignation",
      "datetime": "21-Nov-2019"
    },
    {
      "details": "Balaxi Ventures Limited has informed the Exchange regarding Statement of deviation(s) or variation(s) under Reg. 32 of SEBI (LODR) Regulations 2015",
      "source": "NSE",
      "caption": "Balaxi Ventures Limited - Statement of deviation(s) or variation(s) under Reg. 32",
      "datetime": "30-Oct-2019"
    },
    {
      "details": "Balaxi Ventures Limited has informed the Exchange regarding Board meeting held on October 29, 2019.",
      "source": "NSE",
      "caption": "Balaxi Ventures Limited - Outcome of Board Meeting",
      "datetime": "29-Oct-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Balaxi Pharmaceuticals Ltd has declared <strong>5%</strong> dividend, ex-date: 01 Jul 22",
          "dt": "2022-07-01",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Balaxi Pharmaceuticals Ltd has announced <strong>2:10</strong> stock split, ex-date: 30 May 24",
          "dt": "2024-05-30",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Balaxi Pharmaceuticals Ltd is Rated Strong Sell

2026-08-10 10:10:47

Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 10 August 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Balaxi Pharmaceuticals Gains 1.76%: Quarterly Recovery Amid Lingering Challenges

2026-08-08 14:00:08

Key Events This Week

3 Aug: Stock opens at Rs.24.00, Sensex gains 0.82%

5 Aug: Q1 FY27 results reveal strong revenue recovery

6 Aug: Flat quarterly performance amid long-term challenges reported

7 Aug: Week closes at Rs.24.32, up 1.76% for the week

Week Open

Rs.24.00

Week Close

Rs.24.32

Read full news article

Are Balaxi Pharmaceuticals Ltd latest results good or bad?

2026-08-06 19:22:18

Balaxi Pharmaceuticals Ltd's latest financial results for the quarter ending June 2026 reveal a complex operational landscape. The company reported a net sales figure of ₹80.68 crores, reflecting a year-on-year growth of 14.05%, which is an improvement compared to the previous year's growth of 7.80%. Additionally, the consolidated net profit surged to ₹1.30 crores, marking a significant year-on-year increase of 348.28%, a stark contrast to the negative performance recorded in the same quarter last year. Despite these positive indicators, the operating profit margin, excluding other income, stood at 5.78%, which represents a slight decline from 5.85% in the previous year. This suggests that while revenue growth is being achieved, the company is facing challenges in maintaining profitability levels, indicating potential operational instability. The company's recent performance has led to an adjustment in it...

Read full news article

Balaxi Pharmaceuticals Reports Flat Quarterly Performance Amid Long-Term Challenges

2026-08-06 08:00:25

Balaxi Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended June 2026, signalling a pause in its recent negative trend. Despite achieving record quarterly sales and profitability metrics, the company continues to face challenges in profitability growth and cash reserves, reflecting a complex financial landscape for investors to navigate.

Read full news article

Balaxi Pharmaceuticals Q1 FY27: Strong Revenue Recovery Masks Deep Structural Concerns

2026-08-05 21:18:40

Balaxi Pharmaceuticals Ltd. reported a net profit of ₹1.30 crores for Q1 FY27, representing a substantial sequential improvement of 113.11% from ₹0.61 crores in Q4 FY26 and a dramatic year-on-year surge of 348.28% from ₹0.29 crores in Q1 FY26. The micro-cap pharmaceutical company, with a market capitalisation of ₹136.00 crores, delivered revenue of ₹80.68 crores for the quarter, marking a 14.10% sequential growth and 14.05% year-on-year expansion.

Read full news article

Balaxi Pharmaceuticals Ltd is Rated Strong Sell

2026-07-30 10:10:29

Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 29 May 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 30 July 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Balaxi Pharmaceuticals Ltd is Rated Strong Sell

2026-07-19 10:10:15

Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 29 May 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 19 July 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Balaxi Pharmaceuticals Ltd is Rated Strong Sell

2026-07-08 10:10:27

Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 29 May 2026, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 08 July 2026, providing investors with the latest perspective on the company’s position.

Read full news article

Balaxi Pharmaceuticals Ltd is Rated Strong Sell

2026-06-27 10:10:21

Balaxi Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 29 May 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 27 June 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

View All News